Unnecessary pill-popping leads to dementia, finds new study

A new study by University of Sydney has found that excessive use of medication increases dementia, particularly unnecessary or inappropriate medications. Nearly 2,500 people were examined for the study conducted in collaboration with Yale University and University of Kentucky.

The number of people living with dementia around the world is 50 million. In Australia alone, it is currently 425,000, which means dementia costs the country more than $15 billion per year and it is currently the second leading cause of death in Australia.

"Our study found that following a diagnosis of dementia in older people, medication use increased by 11 per cent in a year and the use of potentially inappropriate medications increased by 17 per cent," said lead author Dr Danijela Gnjidic, from the Faculty of Pharmacy and Charles Perkins Centre at University of Sydney.

The researchers listed inappropriate or unnecessary medications such as sleeping tablets, pain drugs, depression drugs and acid reflux drugs (proton pump inhibitors). "These medications are typically recommended for short term use but are commonly used for long term by people with dementia," she said.

Among the reasons for this include inadequate guidelines, lack of time during physician patient encounters, diminished decision-making capacity, difficulties with comprehension and communication, and difficulties in establishing goals of care.

"The key is to communicate closely with general practitioners, pharmacists and other health professionals to make informed decisions and to practice good medicine management techniques to minimise the risk of side effects.Deprescribing unnecessary medications may improve an individual’s quality of life and can reduce unnecessary healthcare cost," said researchers.

The study has been published Journals of Gerontology: Medical Sciences.

Vitamin B12 Deficiency Sensor Developed to Detect Dementia, Alzheimer Disease in Minutes

In old-age, the frequent occurrence of B12 deficiency could lead to dementia and even Alzheimer’s disease as the body metabolism fails to absorb the vitamin from the diet, requiring an early medical intervention.

To help detect B12 deficieny early, Australia’s University of Adelaide researchers have developed a first of its kind optical sensor using a technique called Raman spectroscopy that can detect vitamin B12 in diluted human blood – a first step towards a low-cost, portable, broadscale vitamin B12 deficiency test.

The sensor, still at proof-of-concept stage, has wide-reaching potential applications. It enables doctors in tracking vitamin B12 levels in high-risk patients and provide an early intervention – to top up immediately vitamin B12 levels when low. Current tests are lengthy and costly too.

Scientists in the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), the Institute for Photonics and Advanced Sensing, and the Schools of Physical Sciences and Medicine, in their presentation today at an international biophotonics conference in Adelaide – the inaugural SPIE BioPhotonics Australasia conference — revealed the new sensor.

“Vitamin B12 deficiency has been shown to be a potential modifiable risk factor for dementia and Alzheimer’s disease and is associated with cognitive decline,” says Dr Georgios Tsiminis, Research Fellow at the University of Adelaide.

“Our sensor is an early first step towards a point-of-care solution for measuring and tracking B12 in healthy ageing adults. This would allow doctors to monitor B12 levels and intervene.”

"Currently our device could not aid in diagnosing vitamin B12 deficiency in a general practice setting… We believe this is a very promising first step towards achieving this goal," she said.

The optical sensor measures B12 in human blood in less than a minute and requires minimum preparation. This is the first demonstration of vitamin B12 being measured in human blood serum without the need for a full lab tests.

The sensor uses an optical measuring technique called Raman spectroscopy which produces a unique optical fingerprint of a target molecule, in this case vitamin B12.